CN Patent

CN114981298B — 用于预防和治疗听力损失的组合物和方法

Assigned to Listening Therapy Co ltd · Expires 2024-08-20 · 2y expired

What this patent protects

描述了使用EGFR信号传导抑制剂来预防或治疗听力损失的方法、药盒和药物组合物。

USPTO Abstract

描述了使用EGFR信号传导抑制剂来预防或治疗听力损失的方法、药盒和药物组合物。

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: CN114981298B
Jurisdiction: CN
Classification: —
Expires: 2024-08-20
Drug substance claim: No
Drug product claim: No
Assignee: Listening Therapy Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.